Comparative Pharmacology
Head-to-head clinical analysis: LACTULOSE versus SODIUM PICOSULFATE MAGNESIUM OXIDE AND ANHYDROUS CITRIC ACID.
Peer-Reviewed Evidence
Head-to-head clinical analysis: LACTULOSE versus SODIUM PICOSULFATE MAGNESIUM OXIDE AND ANHYDROUS CITRIC ACID.
LACTULOSE vs SODIUM PICOSULFATE, MAGNESIUM OXIDE AND ANHYDROUS CITRIC ACID
Comparing the clinical profiles, pharmacokinetic behaviors, and safety indices of these two therapeutic agents.
Lactulose is a non-absorbable disaccharide that is metabolized by colonic bacteria to short-chain fatty acids, primarily lactic acid and acetic acid, resulting in an osmotic effect that increases stool water content and softens stools. In hepatic encephalopathy, lactulose acidifies the colonic lumen, converting NH3 to NH4+, which is poorly absorbed, and reduces systemic ammonia levels.
Sodium picosulfate is a stimulant laxative that is converted by colonic bacteria to the active metabolite bis-(p-hydroxyphenyl)-pyridyl-2-methane, which acts on the colonic mucosa to stimulate peristalsis and increase water and electrolyte secretion. Magnesium oxide and citric acid react in solution to form magnesium citrate, an osmotic laxative that draws water into the intestinal lumen, increasing stool volume and promoting bowel evacuation.
Constipation: 15-30 mL (10-20 g) orally once daily, increased to 45-60 mL (30-40 g) daily if needed. Hepatic encephalopathy: 30-45 mL (20-30 g) orally 3-4 times daily; titrate to produce 2-3 soft stools daily.
Adults: 10 mg sodium picosulfate, 3.5 g magnesium oxide, and 10.97 g anhydrous citric acid (reconstituted in water) as a single oral dose, followed by clear liquids. Two doses may be used in a split-dose regimen: first dose evening before procedure, second dose day of procedure at least 5 hours prior.
None Documented
None Documented
1-2 hours (terminal elimination half-life for lactulose). However, its clinical effect is not dependent on systemic half-life; the drug acts locally in the colon.
Sodium picosulfate active metabolite BHPM: terminal half-life approximately 7.4 hours; clinical duration of laxative effect extends beyond half-life due to colonic residence.
Primarily fecal (unaltered, >90%). Minimal renal excretion (<5% as metabolites). Very small amount (approximately 3%) excreted in urine as unchanged drug.
Sodium picosulfate is primarily excreted in feces (biliary/fecal elimination) as active metabolite BHPM; <5% renal. Magnesium oxide is excreted renally as magnesium ions; absorbed magnesium is eliminated via kidneys. Anhydrous citric acid is metabolized in the Krebs cycle; minimal renal excretion.
Category C
Category C
Laxative
Laxative